Format

Send to

Choose Destination

See 1 citation found by title matching your search:

Pharmacoepidemiol Drug Saf. 2019 Mar;28(3):288-295. doi: 10.1002/pds.4716. Epub 2018 Dec 26.

Maternal and neonatal outcomes after exposure to ADHD medication during pregnancy: A systematic review and meta-analysis.

Author information

1
Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
2
Department of Pediatrics, the Affiliated Hangzhou First People's Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
3
Department of General Internal Medicine, Tongde Hospital of Zhejiang Province, Hangzhou, China.

Abstract

PURPOSE:

Attention-deficit/hyperactivity disorder (ADHD) medications are used by increasing numbers of reproductive-age women. The safety of these medications during pregnancy has not been well described.

METHODS:

A systematic review and meta-analysis was performed to evaluate the adverse maternal and neonatal outcomes associated with exposure to ADHD medication during pregnancy. The PubMed and Embase databases were searched to identify potential studies for inclusion.

RESULTS:

Eight cohort studies that estimated adverse maternal or neonatal outcomes associated with exposure to ADHD medication during pregnancy were included. Exposure to ADHD medication was associated with an increased risk of neonatal intensive care unit (NICU) admission compared with no exposure at any time (risk ratio (RR) 1.88; 95% confidence interval (CI), 1.7-2.08) and compared with women with exposure either before or after pregnancy (RR 1.38; 95% CI, 1.23-1.54; P < 0.001). Exposure to methylphenidate (MPH) was marginally associated with an increased risk for cardiac malformation (RR 1.27; 95% CI, 0.99-1.63; P = 0.065) compared with no exposure. However, exposure to ADHD medication was not associated with an increased risk for other adverse maternal or neonatal outcomes. This analysis was limited by the small number of studies included and the limited adjustments for the possible confounders in the studies.

CONCLUSIONS:

Exposure to ADHD medication during pregnancy does not appear to be associated with adverse maternal or neonatal outcomes. Given the few studies included, further larger, prospective studies that control for important confounders are needed to verify our findings.

KEYWORDS:

attention; hyperactivity; pharmacoepidemiology; prenatal

PMID:
30585374
DOI:
10.1002/pds.4716

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center